Opportunity to Participate in Patient Education Research

Grade 2 Glioma with IDH1 or IDH2 Mutations

Have you, or a loved one been diagnosed with a Grade 2 Glioma with IDH1 or IDH2 mutations? We would love to hear from you! Currently we are working with Fulcrum Research Group to collect the thoughts of patients & caregivers regarding potential new treatment options.

Survey Now Closed

Why is this such a valuable opportunity for patients and caregivers?

Opportunity to provide insights on existing products and treatments for Grade 2 Glioma and share thoughts on their effectiveness, as well as ways the industry can improve.

Learn more about the blood-brain barrier and IDH mutations through this interview.

Offer feedback to the industry on the terminology patients prefer when discussing their health and cancer, particularly around mutations.

What To Expect From Your Participation:

Convenient Scheduling: A one-hour video meeting will be arranged at a time that works best for you.
Informative Discussion: You'll gain insights into the blood-brain barrier and IDH mutations during the interview.
Share Your Perspectives: You'll have the opportunity to provide feedback on Grade 2 Glioma treatments, discuss preferred terminology for health and cancer (especially regarding mutations), and suggest improvements for the industry.
Compensation: Qualifying participants who complete the interview will receive $105 as a token of appreciation for their time and support.

If you would like to share your feedback and help improve research for Grade 2 glioma, please click on the 'Interest Form' button below, fill it out, and our EBCI Clinical Research Coordinator, Shreya Prakash, will contact you.

Interest Form

Adult-type diffuse glioma is a cancer that arises from certain types of brain cells

Astrocytoma, oligodendroglioma, and glioblastoma are all different types of gliomas, and all can hinder normal brain function and cause various symptoms.

IDH Mutations

Genetic mutations have an impact on the glioma classification and potential prognosis. Testing for an IDH mutation in all patients with glioma is essential based on the current guidelines. Mutated IDH gliomas account for about 20% of adult-type diffuse glioma. Each year, 2,400 people are diagnosed with mIDH glioma in the U.S. alone.

Identifying mutations helps precisely classify gliomas and guide patient care plans based on potential outcomes.

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

EBCI In The News

Patient Stories

Patient Support Services

Patient Resource Center